Driving and diabetes: are the changes in the European Union licensing regulations fit for purpose?

Graveling, Alex J; Frier, Brian M · 2018 · Crossref

DOI: 10.15277/bjd.2018.170

archive: archived pipeline: cataloged verified

Get this paper ↗ (DOI — opens at the source; we link to it, we don't host it)

Summary

This commentary evaluates the fitness and purpose of recent changes to European Union (EU) driving licensing regulations for individuals with insulin-treated diabetes, specifically focusing on the implementation of Directive 2016/1106/EC in the UK in January 2018. The authors address the tension between public safety and the practical realities of diabetes management, noting that while hypoglycaemia is the primary threat to driving performance, the overall risk of road traffic accidents for diabetic drivers is modest. The paper critiques the regulatory framework for potentially encouraging the concealment of medical history rather than mitigating risk. The authors analyze the evolution of EU directives, contrasting the strict standards of the 2006 Directive with the amendments introduced in 2018. Key changes for Group 1 licenses (cars and motorcycles) include reducing the mandatory license revocation period from 12 to 3 months following recurrent severe hypoglycaemia and excluding severe hypoglycaemic episodes occurring during sleep from the criteria for license renewal. The commentary reviews evidence regarding driver behavior, citing studies from Denmark and the Czech Republic that demonstrate significant under-reporting of severe hypoglycaemia due to fear of license loss. Additionally, the authors assess the adequacy of current monitoring recommendations, such as the requirement for blood glucose testing every two hours, and the lack of acceptance for continuous glucose monitoring (CGM) data by licensing authorities. The findings indicate that the regulatory changes are likely counterproductive. The reduction of the revocation period to three months is criticized as insufficient time for effective clinical intervention to prevent further hypoglycaemic events. Furthermore, excluding sleep-related hypoglycaemia from licensing criteria is deemed problematic because nocturnal hypoglycaemia can impair cognitive function and mood the following day, thereby affecting driving safety. The authors highlight that the strict previous regulations led to a 55% decline in reported severe hypoglycaemia in Denmark, suggesting that drivers are concealing material facts to retain their licenses. This concealment undermines the regulatory goal of identifying high-risk drivers, as evidenced by surveys showing that a significant proportion of drivers would under-report episodes. The significance of this analysis lies in its conclusion that the current EU regulations fail to effectively promote road safety. The authors argue that the relaxation of rules, driven by political pressure and complaints from diabetes charities, creates a "loophole" where drivers can conceal their medical status with impunity. The commentary calls for a re-evaluation of the regulatory approach, suggesting that the current system does not adequately address the risks posed by impaired awareness of hypoglycaemia or the cognitive aftermath of nocturnal events. Ultimately, the paper asserts that the latest amendments are of debatable benefit and may exacerbate the problem of under-reporting, leaving public safety compromised.

Provenance

The full processing record for this entry. Every stage of this paper's journey through the pipeline is logged — what ran, with which tool and model, how many attempts it took, and when it last completed.

Summary generated by qwen3.6-27b-prismaquant on 2026-06-26; verification: verified.

Topics

Ranked by relevance to this paper. Hover a topic for its definition.

• medical conditions
• licensing policy